![](/img/cover-not-exists.png)
Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Ongoing Phase III Sierra Trial Experience at 6 Study Sites
Nath, Rajneesh, Chu, Bae, Chen, Lingyun, Sadeghi, Amir, Senglaub, Todd, Kaiser, Leo, Saganich, Christopher, Zgaljardic, Michael, Rutar, Frank, Harling, Sean, Liang, Qing, Hari, Parameswaran, van BesieVolume:
26
Journal:
Biology of Blood and Marrow Transplantation
DOI:
10.1016/j.bbmt.2019.12.687
Date:
March, 2020
File:
PDF, 67 KB
2020